罗格列酮、咪达普利单用和联合治疗癌症恶病质的实验性研究-外科学(普外)专业毕业论文.docxVIP

万方数据 万方数据 目 录 英文缩略语表·······················································3 中文摘要···························································4 英文摘要···························································6 前 言···························································9 材料与方法························································11 结 果··························································21 讨 论··························································27 结 论··························································33 参考文献··························································34 综 诉··························································37 致 谢··························································49 2 英文缩写一览表 英文缩写 英文全称 中文名称 RGZ TZDs rosiglitazone thiazolidinediones 罗格列酮 噻唑烷二酮衍生物 PPAR-γ Ang II peroxisome proliferator -activated receptor-gamma angiotensin II 过氧化物酶体增殖蛋白 激活受体-γ 血 管 紧 张素Ⅱ RAS Glut-4 renin-angiotensin system glucose transporter-4 肾素-血管紧张素系统 葡萄糖转运子-4 ACEI DMSO IL-6 TNF-a HIS angiotensin converting enzyme inhibitor dimethyl sulfoxid interleukin-6 tumor necrosis factor-a immunohistochemical score 血管紧张素转换酶抑制剂 二甲基亚砜 白细胞介素-6 肿瘤坏死因子-a 免疫组化评分 NF-κB COPD AIDS CC Glu nuclear factor-κB chronic obstructive pulmonary disease acquired Immune Deficiency Syndrome cancer cachexia blood glucose 组织核因子-κB 慢性阻塞性肺病 获得性免疫缺陷综合症 癌症恶病质 血糖 Tg Alb triglyceride albumin 甘油三酯 白蛋白 Tp total protein 总蛋白 EPA eicosapentenoic acid 二 十 碳 五烯酸 3 罗格列酮、咪达普利单用和联合治疗癌症恶病质的实验性研究 中文摘要 目的 罗格列酮、咪达普利改善癌症恶病质通过不同的作用机制，我们观察罗格 列酮、咪达普利单独和联合应用对小鼠癌症恶病质的治疗作用,并初步探讨其中 可能的发生机制。 方法 于雄性 BALB/C 小鼠前腋窝皮下接种小鼠结肠腺癌 colon26（C26）细胞， 9 天后癌症恶病质模型基本建立。40 只小鼠随机分为 5 组：A 组：健康对照组； B 组：恶病质对照组；C 组：罗格列酮治疗组；D 组：咪达普利治疗组；E 组：罗 格列酮联合咪达普利治疗组。每天按时用药并监测小鼠食物摄入量、小鼠体质量 及肿瘤体积。第 16 天，记录小鼠腓肠肌、附睾脂肪、去瘤体质量，监测血清生 化指标、IL-6、TNF-a 水平，用免疫组化 SP 法检测肿瘤组织中 NF-κB 的表达， 用 real-time PCR 法检测腓肠肌中 atrogin-1 和 MuRF-1 基因的表达情况。 结果 1.癌症恶病质动物模型的建立：后四组小鼠皮下接种 colon-26 细胞 5-6 天后，肿瘤可于腋窝皮下触及。9 天后长至约 1cm3 大小，小鼠开始出现颈背部毛 色发暗、竖立、脱落和活动迟缓，活动减少，虚落等表现；与正常对